Hyperbaric Oxygen vs. Red Light Therapy: Two Different Mechanisms, Compared

Hyperbaric chambers and red-light devices can appear on the same recovery shortlist, but they do not deliver variations of the same intervention. Clinical hyperbaric oxygen therapy combines elevated pressure with near-100% inspired oxygen. The mild chambers InfraCore carries raise pressure while the chamber is pressurized with ambient air. Red-light devices deliver selected wavelengths of light to tissue.

This article is a comparison, not a recommendation. What we can do honestly is describe what each device does, show you what the peer-reviewed research we rely on actually studied — including its limits — and be clear about where the evidence stops. Where you see our opinion, it is labeled as ours.

How each one works

Hyperbaric oxygen

A hyperbaric chamber raises the ambient pressure around your body. As pressure rises — and especially when the concentration of oxygen being breathed also rises — more oxygen dissolves in blood plasma than at normal atmospheric pressure. That dissolved fraction is separate from the oxygen carried by hemoglobin.

One distinction matters more than anything else on this page, because it determines which research applies to what you are buying. Clinical hyperbaric therapy, delivered in hospital and physician-directed settings, typically means breathing close to 100% oxygen at roughly 2.0–3.0 ATA. The mild chambers InfraCore carries operate at 1.3 ATA, and the chamber is pressurized with ambient air.^¹⁰ These are not the same intervention at different intensities. They are different interventions. The hyperbaric studies cited in this article used clinical HBOT, not this mild ambient-air configuration.

Keep that in mind while reading what our cited research actually studied:

• Thom et al. measured mobilization of circulating CD34+ progenitor cells following a clinical exposure — 100% oxygen at 2.0 ATA for two hours.^¹ It measured cell mobilization. It did not measure healing, recovery, or any clinical outcome.
• Schiavo et al. is an evidence-based narrative review of hyperbaric oxygen in chronic neuropathic pain.^² It discusses proposed pathways including hyperoxia-driven edema resolution and nitric-oxide-dependent endogenous opioid release. Its own abstract states that hyperbaric oxygen's role and efficacy in chronic neuropathic pain remain unclear, and several of the pathways it describes are preclinical or specific to particular conditions. We are carrying that uncertainty forward rather than paraphrasing past it.

Red light

Red light therapy sits inside a broader research and clinical field called photobiomodulation (PBM). The two are not interchangeable. PBM covers a wider range of devices and wavelengths than consumer red-light panels — laser systems very much included — so a study labeled PBM does not automatically describe the LED device in your living room. Consumer red-light devices commonly use red and near-infrared LEDs, although wavelength combinations vary by device.

One of the leading proposed mechanisms involves cytochrome c oxidase, an enzyme in the mitochondrial respiratory chain. Researchers believe absorption of red and near-infrared light may influence mitochondrial signaling, ATP production, oxidative balance, and pathways involved in cellular repair.^⁷ That word may is doing real work, and we are not going to quietly upgrade it.

What our cited research actually studied:

• Ferraresi, Huang and Hamblin reviewed PBM in human muscle tissue.^⁵
• Canez et al. published a 2025 systematic review with meta-analysis covering PBM alongside intermittent pneumatic compression and neuromuscular electrical stimulation for muscle recovery.^⁶
• Chow et al., in The Lancet, examined low-level laser therapy for neck pain across 16 randomized trials and reported reductions in pain intensity.^⁸ The devices in those trials were lasers. That finding does not transfer to consumer LED panels as a category, and we are not going to let it.

On depth and dose, two things that get run together: wavelength influences how deep light reaches, but penetration is not a fixed specification you can read off a box. Penetration and delivered dose are related, but they are not interchangeable. At the treatment surface, radiant exposure is determined by irradiance and exposure time; distance matters because it can change the irradiance that actually reaches that surface.^⁷ PBM often shows a biphasic dose response, where too little may be ineffective and too much can reduce the desired response.^⁷

Side by side

Three columns, not two — because collapsing clinical hyperbaric therapy and a mild consumer chamber into one column is exactly how clinical evidence gets read as applying to a home purchase.

	Clinical HBOT	Mild consumer chamber (what InfraCore sells)	Red light / PBM devices
Setting	Hospital, clinic, physician-directed	Home or other settings under prescriber and manufacturer direction	Home, clinic, gym
Pressure and gas	Typically close to 100% oxygen at roughly 2.0–3.0 ATA	1.3 ATA (4.4 PSI) — the figure stated in every Summit to Sea manual we hold. Chamber pressurization uses ambient air; Summit to Sea instructs users not to inflate the chamber with enriched oxygen¹⁰	No pressure involved
What the device does	Raises pressure and inspired oxygen so more oxygen dissolves in plasma	Raises ambient-air pressure modestly; it does not reproduce clinical HBOT's combination of higher pressure and near-100% inspired oxygen	Emits red and near-infrared wavelengths onto tissue
Status of the mechanism and evidence	The physics of dissolved oxygen under pressure is well characterized. In the one clinical area reviewed here — chronic neuropathic pain — the cited review states that HBOT's role and efficacy remain unclear²	The clinical HBOT studies cited in this article did not study this pressure-and-gas configuration	Cytochrome c oxidase absorption is a leading proposed mechanism, not a settled one⁷
Delivery	Systemic — whole body inside the chamber	Whole-body exposure to mild ambient-air pressurization	Wherever the light reaches. Ranges from a face mask to a full-body bed
Reach	Systemic, via plasma and bloodstream	The whole body experiences the pressure change; that does not establish clinical equivalence to HBOT	Wavelength influences depth; penetration is not a fixed specification. Delivered dose is set by irradiance and exposure time at the treatment surface
Session length	Set by the treating clinician	Follow the manufacturer's instructions for your specific chamber	Follow the manufacturer's instructions for your specific device
Regulatory status	Hyperbaric chambers are Class II devices under 21 CFR 868.5470, product code CBF⁴	Summit to Sea's current owner's manuals label the models we carry as Class II devices requiring a prescription¹⁰	Regulatory status varies by exact device. Verify any clearance claim and labeled indication in the FDA 510(k) database; do not infer clearance from the PBM category
What the clearance actually covers	Depends on the specific device and its labeled indications	FDA record K072757, cleared in 2008, names The Shallow Dive, The Dive and The Grand Dive, and lists their cleared indication as the treatment of acute mountain sickness (AMS), as prescribed by or under the direction of a physician.⁴ That is the full labeled indication in this record; it does not establish other uses. Its comparison table describes The Shallow Dive at 1.2 ATA and the other two chambers at 1.3 ATA. Current manuals do not establish that every present-day configuration sold under those names is identical to the configuration reviewed in that record. Ask for the K-number covering the exact model and configuration you are buying	For an FDA-cleared red-light or PBM device, clearance covers only that exact device and its labeled indications
Space required	Not applicable — you travel to it	A dedicated room or a large floor area	Masks and pads require little dedicated floor space; full-body beds and pods require substantially more
Catalog price span (all models, as of 2026-08-31)	Not sold by InfraCore	$7,995–$21,995	$94–$89,900

A note on that last row: these are full-category spans across every product we list, not comparable tiers. A $94 light pad and an $89,900 full-body bed sit in the same column. A face mask is not a smaller version of a chamber, and the spans should not be read as a like-for-like price comparison.

Our view at InfraCore: when a chamber makes sense

This is our opinion, not a research finding.

The thing a chamber gives you that no light device does is a pressurized whole-body environment. That is the actual distinction — not "whole body versus targeted," because some red-light devices are full-body too. In our concierge process we consider a chamber for a buyer who specifically wants that pressurized environment, who has a room that can genuinely hold one, and who is comfortable with equipment that has to be operated by the manufacturer's instructions rather than casually.

Two regulatory facts belong in that decision.

Summit to Sea's current owner's manuals label the chamber models InfraCore carries as prescription devices.^¹⁰ The K072757 record carries the same restriction for the models it names: federal law restricts those devices to sale by or on the order of a physician.^⁴

And the labeled indication in that 2008 record is narrow. FDA's 2008 clearance record K072757 names The Shallow Dive, The Dive and The Grand Dive, and lists their cleared indication as the treatment of acute mountain sickness (AMS), as prescribed by or under the direction of a physician.^⁴ That is the full labeled indication in this record; it does not establish other uses.

The pressure table in the 2008 record does not fully match the current manuals. It describes The Shallow Dive at 1.2 ATA and the other two chambers at 1.3 ATA, while the current manuals for every model InfraCore carries state 1.3 ATA.^⁴˒¹⁰ Current manuals do not establish that every present-day configuration sold under those names is identical to the configuration reviewed in that record. So a shared product name is not by itself evidence of shared clearance: ask for the K-number covering the exact model and configuration you are buying — ours included.

So: we do not recommend chambers for particular medical conditions. That conversation belongs with your physician, not with a wellness retailer.

And read the FDA's August 2025 letter to health care providers before you buy anything in this category. It was issued after reports of fires involving serious injuries and deaths in hyperbaric devices, and it addresses fire prevention, grounding, control of prohibited items, appropriate clothing, staff training, and appropriate patient monitoring and supervision throughout treatment.^³ The FDA states that the root cause of those events is not known, and that it believes serious adverse events with these devices are rare. Both halves of that belong here. This is equipment, not furniture.

Our view at InfraCore: when red light makes sense

Also our opinion.

The smaller end of the red light range — masks, pads, single panels — asks less of a room and less of a budget than a chamber does, and that is where most of the entry points in our catalog sit. We consider those for a buyer who wants something that fits an existing routine and an existing space, or who wants to begin with one area of the body rather than all of it. That reasoning does not extend up the range. At the top of our catalog, the full-body bed's price exceeds that of any chamber we sell; space requirements must be compared separately.

One caution worth repeating: compare devices on independently verified irradiance measured at a realistic treatment distance, not on a headline number taken at zero inches. And remember that irradiance is one input to dose, not the whole of it — higher output is not automatically better.^⁷

Using both: what the evidence does and doesn't support

When people ask about using both, here is the straight answer: synergy is not established.

We located one directly relevant human trial. In July 2026, Fahmy et al. randomized 40 patients aged 55 to 70 with neuropathic foot ulcers to standard care, or to standard care plus clinical hyperbaric oxygen followed by polarized light therapy — 20 patients per arm.^⁹ The outcomes measured were ulcer volume, transcutaneous oxygen tension (TcPO2) and Michigan Neuropathy Questionnaire scores, assessed at baseline, two weeks and four weeks. The combined group improved significantly on all three relative to controls.

But the study had no hyperbaric-only arm and no light-only arm. It could not isolate what either modality contributed, and it could not test whether the combined effect exceeded what would be expected from the individual effects — a combination that beats standard care may be additive rather than synergistic, and this design cannot tell those apart. It also used clinical hyperbaric oxygen rather than a mild consumer chamber, and polarized light rather than the red and near-infrared LED systems we sell.

In the directly relevant human evidence we located, one small trial studied the combination, in one clinical population, and it did better than standard care. The study does not establish transferability to a mild chamber and an LED panel in a spare bedroom. We are not going to hand you a stacking order, because no study we can point you to established an optimal one.

What we can tell you — and this is concierge judgment, not evidence — is what actually comes up when someone owns both. Where does the chamber physically live, and does the light device have to share the room? Whose schedule absorbs two sessions instead of one? What does the electrical situation look like? And if both are on the list but only one is in this year's budget, which one fits the room and the routine you actually have, rather than the one you are imagining.

Those are the questions we can help with. Whether the two together do more than the sum of their parts, we can't — not yet, and not honestly.

This article compares mechanisms rather than telling you how either one feels, and that is deliberate. What a device does, what a study actually measured, and where the evidence runs out are things I can show you and you can check for yourself. Because personal testimony is not something a reader can independently verify, I would rather hand you the part you can. If that makes this a drier read, I will take that trade.

— Bree Garrett, Founder